{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rule S"],"funding":["Cancer Research UK","National Institute for Health Research (NIHR)"],"pagination":["235-40"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4938327"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["101(2)"],"pubmed_abstract":["Mantle cell lymphoma is an incurable and generally aggressive lymphoma that is more common in elderly patients. Whilst a number of different chemotherapeutic regimens are active in this disease, there is no established gold standard therapy. Rituximab has been used widely to good effect in B-cell malignancies but there is no evidence that it improves outcomes when added to chemotherapy in this disease. We performed a randomized, open-label, multicenter study looking at the addition of rituximab to the standard chemotherapy regimen of fludarabine and cyclophosphamide in patients with newly diagnosed mantle cell lymphoma. A total of 370 patients were randomized. With a median follow up of six years, rituximab improved the median progression-free survival from 14.9 to 29.8 months (P<0.001) an"],"journal":["Haematologica"],"pubmed_title":["The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial."],"pmcid":["PMC4938327"],"funding_grant_id":["NF-SI-0513-10144","NF-SI-0507-10370","15953","15556","CRUK/06/013"],"pubmed_authors":["Seymour JF","Kruger A","Toncheva M","Walewski J","Johnson S","Jack A","Kirkwood AA","Smith P","Follows G","Gambell J","Hillmen P","Linch D","Johnson PW","Bolam S","Pocock C","Rule S"],"additional_accession":[]},"is_claimable":false,"name":"The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.","description":"Mantle cell lymphoma is an incurable and generally aggressive lymphoma that is more common in elderly patients. Whilst a number of different chemotherapeutic regimens are active in this disease, there is no established gold standard therapy. Rituximab has been used widely to good effect in B-cell malignancies but there is no evidence that it improves outcomes when added to chemotherapy in this disease. We performed a randomized, open-label, multicenter study looking at the addition of rituximab to the standard chemotherapy regimen of fludarabine and cyclophosphamide in patients with newly diagnosed mantle cell lymphoma. A total of 370 patients were randomized. With a median follow up of six years, rituximab improved the median progression-free survival from 14.9 to 29.8 months (P<0.001) an","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb","modification":"2025-05-18T11:57:27.91Z","creation":"2025-05-18T11:57:27.91Z"},"accession":"S-EPMC4938327","cross_references":{"pubmed":["26611473"],"doi":["10.3324/haematol.2015.128710"]}}